Bristol-Myers to buy diabetes drug maker for $5B

(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.

Bristol-Myers says it will pay $31 per share for Amylin in a cash tender offer.

Including Amylin's debt and a contractual payment obligation to Eli Lilly & Co., the deal is worth about $7 billion.

The deal was announced Friday. After it is complete, Bristol-Myers will enter into an alliance with drug maker AstraZeneca to develop and commercialize Amylin's portfolio of drugs. AstraZeneca will pay Bristol-Myers $3.4 billion in , and both companies will share profits and losses.

Bristol-Myers says the deal will hurt earnings in 2012 and 2013 by 3 cents per .

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA: Bristol-Myers diabetes drug appears safe

Mar 30, 2009

(AP) -- A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.

Amylin's long-delayed diabetes drug gets FDA nod

Jan 28, 2012

Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta.

Recommended for you

Viagra ads target women for first time

15 hours ago

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments